

[REDACTED]

---

**From:** [REDACTED]@emory.edu  
**Sent:** Friday, December 08, 2006 12:50 PM  
**To:** Adkison, Claudia R  
**Subject:** FW:

**FROM DEAN THOMAS J. LAWLEY, M.D.**

FYI

-----Original Message-----

**From:** Charles B. Nemeroff [mailto:[REDACTED]@emory.edu]  
**Sent:** Wednesday, December 06, 2006 9:42 PM  
**To:** [REDACTED]  
**Cc:** Tom Lawley; [REDACTED]; [REDACTED]  
**Subject:**

Dear Dr. [REDACTED],

This letter represents a follow up to our discussion at the ACNP annual meeting in which I informed you that I would be unable to serve as a coauthor or continue to collaborate with you on the Lundbeck Clinical Trials database that we had previously discussed. As you know, I have made the firm decision to no longer serve as an individual consultant to Pharmaceutical companies, and moreover, will severely limit my membership to only a few Pharmaceutical Company Scientific Advisory Boards associated with very early candidates in the drug development pipeline. I certainly wish you the best with the project which has a number of very talented academic investigators. I hope to see you during my planned trip to Europe in the spring when I will deliver invited lectures at international meetings.

I remain enthusiastic about the project and wish you and Lundbeck the best success. This decision is based solely on my wish to remove any perception of conflict of interest in my position of leadership of the Department of Psychiatry and Behavioral Sciences at Emory so that I can focus on the faculty in the department, clinical service and teaching, as well as my own NIH funded research. I look forward to seeing you before too long.

Sincerely,  
Charlie

Charles B. Nemeroff, MD, PhD